A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
A phase 3 trial of Nivolumab, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% is a phase 3 interventional study registered as NCT06561386 by Bristol-Myers Squibb, with 1000 participants planned, started 2024-10-07 and due to reach its primary completion in 2030-07-30. Interventions recorded: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Nivolumab.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Nivolumab.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.